Trial Search Results
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.
Stanford is currently accepting patients for this trial.
Targeted Therapy Technologies, LLC
- Drug: Episcleral Celecoxib
- Age >= 18 years;
- Visual acuity letter score in study eye < 70 and ≥ 25 letters (approximate Snellen
equivalent 20/32 to 20/320);
- Ophthalmoscopic evidence of center-involved macular edema, within the central subfield
(CSF); • Inflammatory disorders of the sclera, choroid, retina or vitreous
- Inability to understand informed consent, cooperate with testing or return to follow
- Pregnant or lactating women;
- Co-existent ocular disorder of the cornea, lens or media that will interfere with
assessment of safety or efficacy.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study